

Hepatitis C in Primary Care & Drug and Alcohol Settings

Treating hepatitis C in people who inject drugs

People who inject drugs (PWID) represent approximately 90% of newly acquired hepatitis C (HCV) infections. Clinicians working with PWID play an important role in reducing HCV-related morbidity and mortality through early diagnosis and treatment.

With the advent of new, well-tolerated, short-course direct acting antiviral (DAA) HCV regimens with cure rates >95%, there is an opportunity to vastly improve the health outcomes of people living with HCV.

This program is designed for addiction medicine specialists, OST prescribers, family physicians and other medical staff working with people who inject drugs. Through online learning and a face-to-face workshop, delivered by local experts, participants will gain the skills to confidently manage hepatitis C in their setting.

Upon completion of this program, participants will be able to:

- Describe the risk factors for HCV infection, enabling effective practice screening processes and prevention education
- Demonstrate competence interpreting clinical information to effectively diagnose HCV
- Demonstrate competence in liver disease assessment
- Demonstrate understanding of DAA therapy for the treatment of HCV and competence in selecting and prescribing appropriate therapy
- Monitor patients on treatment and post-treatment appropriately

Date:

Tuesday, 29th October 2019

Time:

8:30am - 4:00pm

Venue:

Holiday Inn Hotel & Suites Downtown
1110 Howe Street
Vancouver, BC V6Z 1R2, Canada

Cost:

The course is free of charge and fully catered. Places are limited - registration is essential.

Registration link:

<https://ashm.eventsair.com/vancouver-29-October-2019-hep-c/registration>

Register before:

Thursday, 18 October 2019

More information:

For further details contact education@ashm.org.au

Certification

This Group Learning program has been reviewed by the College of Family Physicians of Canada and is awaiting provincial certification by the College's BC Chapter.

About INHSU

This Symposium is convened by the International Network on Hepatitis in Substance Users (INHSU), an international organisation dedicated to scientific knowledge exchange, knowledge translation, and advocacy focused on hepatitis C prevention and care among people who use drugs.

This workshop has been funded through an unrestricted grant from AbbVie Canada and Gilead Sciences Canada. AbbVie and Gilead have had no input into the tone, content or emphasis of the material used at this course.



ashm



UNSW
SYDNEY



Kirby Institute



CanHepC
Canadian Network on Hepatitis C
Réseau Canadien sur l'Hépatite C



CASL
ACEP
Association Canadienne
pour l'Étude du Foie



CATIE
Canada's source for
HIV and hepatitis C
information